Genocea Biosciences (GNCA) Given a $5.00 Price Target by HC Wainwright Analysts
HC Wainwright set a $5.00 price objective on Genocea Biosciences (NASDAQ:GNCA) in a research report report published on Wednesday. The brokerage currently has a buy rating on the biotechnology company’s stock.
Separately, Zacks Investment Research raised Genocea Biosciences from a hold rating to a buy rating and set a $0.75 target price for the company in a report on Monday, November 5th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $3.35.
Shares of GNCA traded down $0.05 during mid-day trading on Wednesday, reaching $0.68. The company had a trading volume of 80,214 shares, compared to its average volume of 220,168. Genocea Biosciences has a twelve month low of $0.49 and a twelve month high of $1.39. The company has a current ratio of 4.01, a quick ratio of 4.01 and a debt-to-equity ratio of 1.91. The stock has a market cap of $62.38 million, a PE ratio of -0.34 and a beta of 1.14.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GNCA. California State Teachers Retirement System grew its position in Genocea Biosciences by 166.6% during the 1st quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 78,469 shares during the last quarter. LMR Partners LLP bought a new stake in Genocea Biosciences during the 2nd quarter worth approximately $175,000. Schwab Charles Investment Management Inc. bought a new stake in Genocea Biosciences during the 1st quarter worth approximately $177,000. DRW Securities LLC bought a new stake in Genocea Biosciences during the 2nd quarter worth approximately $205,000. Finally, Fosun International Ltd bought a new stake in Genocea Biosciences during the 3rd quarter worth approximately $323,000. Institutional investors and hedge funds own 60.23% of the company’s stock.
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
See Also: What are CEFs?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.